IP Library › Granted Patent US 12,258,619
Granted Patent B2
US 12,258,619 · App. 18/765,750 · Granted Mar 25, 2025

Sample splitting for multiplexed detection of nucleic acids without amplification

Inventor: Phillip Belgrader (San Diego, CA)
Assignee: VedaBio, Inc.
C12Q1/6823C12N9/22C12N15/111C12Q1/44C12Q1/6806G01N21/6486C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,619
App. No.
18/765,750
Granted
Mar 25, 2025
Kind
B2
Abstract

The present disclosure relates to multiplex assay methods used to detect target nucleic acids of interest from several to many sources in a sample without amplification of the target nucleic acids of interest. The methods involve partitioning of first ribonucleoprotein complexes to detect short sequences from several to many loci scattered throughout a single source genome, and the addition of signal boosting second ribonucleoprotein complexes and reporter moieties.

Claims (39)

1. A method for identifying one or more target nucleic acids of interest from two or more source organisms in a sample comprising the steps of:

obtaining a sample;

lysing the source organisms and fractionating nucleic acids obtained from the lysed source organisms in the sample, wherein the nucleic acids are fractionated into lengths of 50 bp to 100,000 bp;

designing a plurality of first guide nucleic acids (gRNA1s) complementary to a plurality of loci in each genome of the two or more source organisms;

forming first ribonucleoprotein complexes (RNP1s) comprising a first nucleic acid-guided nuclease and the gRNA1s; wherein the first nucleic acid-guided nuclease exhibits both cis- and trans-cleavage activity and wherein the RNP1s are formed in partitions where different partitions comprise different gRNA1 sequences;

providing a reaction mixture comprising:

second ribonucleoprotein complexes (RNP2s) comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acids of interest; wherein the second nucleic acid-guided nuclease exhibits both cis- and trans-cleavage activity; and

a plurality of blocked nucleic acid molecules comprising a sequence corresponding to the second gRNA, wherein a K d of the blocked nucleic acid molecules binding to the RNP2s is from 100 nM to 100 μM;

contacting the RNP1s in each partition with the reaction mixture and the fractionated nucleic acids in the sample under conditions that allow the target nucleic acids of interest in the sample to bind to RNP1, wherein upon binding of target nucleic acids of interest the RNP1s become active initiating trans-cleavage of at least one of the plurality of blocked nucleic acid molecules thereby producing at least one unblocked nucleic acid molecule, wherein a K d of the at least one unblocked nucleic acid molecule binding to the RNP2 is from 100 fM to 1 aM and wherein the at least one unblocked nucleic acid molecule binds to RNP2 initiating trans-cleavage of at least one further blocked nucleic acid molecule; and

detecting cleavage products from each partition, thereby detecting the target nucleic acids of interest in the sample.

2. The method of claim 1 , wherein one or both of RNP1 and RNP2 comprise a nucleic acid-guided nuclease selected from Cas3, Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas14, Cas12h, Cas12i, Cas12j, Cas13a, or Cas13b.

3. The method of claim 1 , wherein the reaction mixture further comprises a reporter moiety.

4. The method of claim 3 , wherein the reporter moiety comprises a fluorescent, chemiluminescent, radioactive, colorimetric or other optical signal.

5. The method of claim 4 , wherein the reporter moiety comprises the fluorescent signal.

6. The method of claim 4 , wherein the reporter moiety comprises the chemiluminescent signal.

7. The method of claim 4 , wherein the reporter moiety comprises the colorimetric signal.

8. The method of claim 3 wherein the reporter moiety is not operably linked to the blocked nucleic acid molecules.

9. The method of claim 3 , wherein the reporter moiety is operably linked to the blocked nucleic acid molecules.

10. The method of claim 1 , wherein the lysing step is performed at 95° C.

11. The method of claim 1 , wherein the lysing step is performed using bead beating.

12. The method of claim 1 , wherein the lysing step is performed using sonication.

13. The method of claim 1 , wherein the lysing step is performed using a lysing buffer comprising EDTA.

14. The method of claim 1 , wherein the lysing step is performed using a lysing buffer comprising TCEP.

15. The method of claim 1 , wherein the lysing step is performed using a lysing buffer comprising DTT.

16. The method of claim 1 , wherein the lysing step is performed using a lysing buffer comprising isothiocyanate.

17. The method of claim 1 , further comprising a nucleic acid purification step after the lysing step.

18. The method of claim 1 , wherein the partitions are wells.

19. The method of claim 1 , wherein the partitions are spots separated by interstitial regions.

20. The method of claim 1 , wherein the partitions are droplets.

21. The method of claim 1 , wherein the nucleic acids are fractionated into lengths of 50 bp to 5,000 bp.

22. The method of claim 21 , wherein the nucleic acids are fractionated into lengths of 100 bp to 1,000 bp.

23. The method of claim 22 , wherein the nucleic acids are fractionated into lengths of 100 bp to 500 bp.

24. The method of claim 1 , wherein the nucleic acids are fractionated into lengths of 30 bp to 500 bp.

25. The method of claim 24 , wherein the nucleic acids are fractionated into lengths of 30 bp to 100 bp.

26. The method of claim 1 , wherein at least three gRNA1s complementary to loci in each genome of each source organism are designed.

27. The method of claim 26 , wherein at least four gRNA1s complementary to loci in each genome of each source organism are designed.

28. The method of claim 27 , wherein at least five gRNA1s complementary to loci in each genome of each source organism are designed.

29. The method of claim 28 , wherein at least ten gRNA1s complementary to loci in each genome of each source organism are designed.

30. The method of claim 29 , wherein at least twenty gRNA1s complementary to loci in each genome of each source organism are designed.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2024
From: BELGRADER, PHILLIP
To: VEDABIO, INC.
Reel/Frame 067926/0450 →
Continuity (3)
Continuation 18406159 · Jan 7, 2024
Provisional Application 63438147 · Jan 10, 2023
Related Publication 20250002977A1 · Jan 2, 2025
References Cited (127)
US 10253365B1 · Doudna et al. · 2019 [cited by applicant]
US 10266886B2 · Abudayyeh et al. · 2019 [cited by applicant]
US 10266887B2 · Abudayyeh et al. · 2019 [cited by applicant]
US 10337051B2 · Doudna et al. · 2019 [cited by applicant]
US 10377998B2 · Zhang et al. · 2019 [cited by applicant]
US 10494664B2 · Doudna et al. · 2019 [cited by applicant]
US 10533152B1 · Belgrader et al. · 2020 [cited by applicant]
US 11021740B2 · Abudayyeh et al. · 2021 [cited by applicant]
US 11060115B2 · Severinov et al. · 2021 [cited by applicant]
US 11104937B2 · Abudayyeh et al. · 2021 [cited by applicant]
US 11118224B2 · Doudna et al. · 2021 [cited by applicant]
US 11149259B2 · Zhang et al. · 2021 [cited by applicant]
US 11174470B2 · Harrington et al. · 2021 [cited by applicant]
US 11174515B2 · Abudayyeh et al. · 2021 [cited by applicant]
US 11273442B1 · Chen et al. · 2022 [cited by applicant]
US 11421250B2 · Severinov et al. · 2022 [cited by applicant]
US 11447824B2 · Doudna et al. · 2022 [cited by applicant]
US 11584955B2 · Wang et al. · 2023 [cited by applicant]
US 20100286082A1 · Breaker et al. · 2010 [cited by applicant]
US 20140377748A1 · Tan et al. · 2014 [cited by applicant]
US 20160040189A1 · Kennedy et al. · 2016 [cited by applicant]
US 20160083785A1 · Bone et al. · 2016 [cited by applicant]
US 20160186213A1 · Zhang et al. · 2016 [cited by applicant]
US 20180023081A1 · Hagedorn et al. · 2018 [cited by applicant]
US 20180155716A1 · Zhang et al. · 2018 [cited by applicant]
US 20180282722A1 · Jakimo et al. · 2018 [cited by applicant]
US 20190046989A1 · Ririe et al. · 2019 [cited by applicant]
US 20190112648A1 · Schaal et al. · 2019 [cited by applicant]
US 20190201550A1 · Maeder et al. · 2019 [cited by applicant]
US 20190241954A1 · Doudna et al. · 2019 [cited by applicant]
US 20190256900A1 · Zhang et al. · 2019 [cited by applicant]
US 20190344269A1 · Johnson et al. · 2019 [cited by applicant]
US 20200010879A1 · Doudna et al. · 2020 [cited by applicant]
US 20200056167A1 · Dong et al. · 2020 [cited by applicant]
US 20200157611A1 · Qi et al. · 2020 [cited by applicant]
US 20200165594A1 · Zhang et al. · 2020 [cited by applicant]
US 20200277600A1 · Zhang et al. · 2020 [cited by applicant]
US 20200392473A1 · Zhang et al. · 2020 [cited by applicant]
US 20210102183A1 · Cameron et al. · 2021 [cited by applicant]
US 20210102242A1 · Chen et al. · 2021 [cited by applicant]
US 20210108267A1 · Zhang et al. · 2021 [cited by applicant]
US 20210163944A1 · Zhang et al. · 2021 [cited by applicant]
US 20210166783A1 · Shmakov et al. · 2021 [cited by applicant]
US 20210269866A1 · Zhang et al. · 2021 [cited by applicant]
US 20210317527A1 · Doudna et al. · 2021 [cited by applicant]
US 20210388437A1 · Doudna et al. · 2021 [cited by applicant]
US 20220025463A1 · Abudayyeh et al. · 2022 [cited by applicant]
US 20220333208A1 · Gootenberg et al. · 2022 [cited by applicant]
US 20230193368A1 · Rananaware et al. · 2023 [cited by applicant]
CN 113324956 · 2021 [cited by applicant]
CN 114058679A · 2022 [cited by applicant]
CN 114262730A · 2022 [cited by applicant]
WO WO2014143228A1 · 2014 [cited by applicant]
WO WO2016201138A1 · 2016 [cited by applicant]
WO WO2020191248 · 2020 [cited by applicant]
WO WO2020191376 · 2020 [cited by applicant]
WO WO2021021532A1 · 2021 [cited by applicant]
WO WO2021108717A2 · 2021 [cited by applicant]
WO WO2021146534A1 · 2021 [cited by applicant]
WO WO2021236651A1 · 2021 [cited by applicant]
WO WO2021243276 · 2021 [cited by applicant]
WO WO2022061166A1 · 2022 [cited by applicant]
WO WO2022133108A2 · 2022 [cited by applicant]
WO WO2022266513A2 · 2022 [cited by applicant]
WO WO2023278629A1 · 2023 [cited by applicant]
WO WO2023287669A2 · 2023 [cited by applicant]
WO WO2023015259A2 · 2023 [cited by applicant]
WO WO2023056451A1 · 2023 [cited by applicant]
WO WO2023081902A1 · 2023 [cited by applicant]
WO WO2023114052A1 · 2023 [cited by applicant]
WO WO2023114090A2 · 2023 [cited by applicant]
WO WO20242067133A1 · 2024 [cited by applicant]
Li, et al., “Applying CRISPR-Cas12a as Signal Amplifier to Construct Biosensors for Non-DNA Targets in Ultra-low Concentrations”, ACS Sensors, doi: 10.1021/acssensors.9b02305, pp. 1-23, Mar. 12, 2020. [cited by applicant]
Kim, et al., “Chimeric crRNAs with 19 DNA residues in the guide region show retained DNA cleavage activity of Cas9 with a potential to improve the specificity”, The Royal Society of Chemistry, pp. 1-16, 2019. [cited by applicant]
Kim, et al., “Enhancement of target specificity of CRISPR-Cas12a by using a chimeric DNA-RNA guide”, Nucleic Acids Research, doi: 10.1093/nar/gkaa605, vol. 48, No. 15, pp. 8601-8616, Jul. 20, 2020. [cited by applicant]
Swarts, et al., “Mechanistic Insights into the Cis- and Trans-acting Deoxyribonuclease Activities of Cas12a”, Mol Cell, doi: 10.1016/j.molcel.2018.11.021, pp. 1-28, Feb. 7, 2019. [cited by applicant]
Nguyen, et al., “Enhancement of trans-cleavage activity of Cas12a with engineered crRNA enables amplified nucleic acid detection”, Nature Communications, doi: 10.1038/s41467-020-18615-1, pp. 1-13, 2020. [cited by applicant]
Ooi, et al., “An engineered CRISPR-Cas12a variant and DNA-RNA hybrid guides enable robust and rapid COVID-10 testing”, Nature Communications, doi: 10.1038/s41467-021-21996-6, pp. 1-23, 2021. [cited by applicant]
Shi, et al., “A CRISPR-Cas autocatalysis-driven feedback amplification network for supersensitive DNA diagnostics”, Science Advances, doi: 10.1126/sciadv.abc7802, pp. 1-9, Jan. 27, 2021. [cited by applicant]
The Board of Trustees of the University of Illinois, “CRISPR Cascade”, International PCT Application No. PCT/US22/33985, filed Jun. 17, 2022. [cited by applicant]
Chen, et al., “CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity”, Howard Hughes Medical Institute, Science, 360(6387), pp. 436-439, Apr. 27, 2018. [cited by applicant]
Liu, et al., “Accelerated RNA detection using tandem CRISPR nucleases”, Nature Chemical Biology, vol. 17, doi:10.1038/s41589-021-0084202, pp. 982-988, Sep. 2021. [cited by applicant]
Gootenberg, et al., “Nucleic acid detection with CRISPR-Cas13a/C2c2”, Science, doi:10.1126/science.aam9321, pp. 438-442, Apr. 28, 2017. [cited by applicant]
Fozouni, et al., “Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy”, Cell, doi.org/10.1016/j.cell.2020.12.001, pp. 323-333, Jan. 21, 2021. [cited by applicant]
Kaminski, et al., “CRISPR-based diagnostics”, Nature Biomedical Engineering, vol. 5, doi.org/10.1038/s41551-021-00760-7, pp. 643-656, Jul. 2021. [cited by applicant]
Zhou, et al., “CRISPR/Cas13a Powered Portable Electrochemiluminescence Chip for Ultrasensitive and Specific MiRNA Detection”, Advanced Science News, doi: 10.1002/advs.201903661, pp. 1-10, 2020. [cited by applicant]
Zhao, et al., “CRISPR-Cas13a system: A novel tool for molecular diagnostics”, Frontiers in Microbiology, doi:10.3389/fmicb.2022.1060947, pp. 1-18, Dec. 8, 2022. [cited by applicant]
Zhou, et al., “A Decade of CRISPR Gene Editing in China and Beyond: A Scientometric Landscape”, The CRISPR Journal, vol. 4, No. 3, doi:10.1089/crispr.2020.0148, pp. 313-320, 2021. [cited by applicant]
Shinoda, et al., “Automated amplification-free digital RNA detection platform for rapid and sensitive SARS-CoV-2 diagnosis”, Communications Biology, doi.org/10.1038/s42003-022-03433-6, pp. 1-8, May 26, 2022. [cited by applicant]
Gupta, et al., “Cas13d: A New Molecular Scissor for Transcriptome Engineering”, Frontiers in Cell and Developmental Biology, vol. 10, doi:10.3389/fcell.2022.866800, pp. 1-22, Mar. 31, 2022. [cited by applicant]
Schunder, et al., “First indication for a functional CRISPR/Cas system in Francisella tularensis”, International Journal of Medical Microbiology, vol. 303, Issue 2, doi:10.1016/j.ijmm.2012.11.004, pp. 1-29, Mar. 2013. [cited by applicant]
Sha, et al., “Cascade CRISPR/cas enables amplification-free microRNA sensing with fM-sensitivity and single-base-specificity”, ChemComm, doi:10.1039/d0cc06412b, pp. 247-250 and 1-15, 2021. [cited by applicant]
Yang, et al., “Engineered LwaCas13a with enhanced collateral activity for nucleic acid detection”, Nature Chemical Biology, vol. 19, doi:10.1038/s41589-022-01135-y, pp. 45-54, Jan. 2023. [cited by applicant]
East-Seletsky, et al., “RNA targeting by functionally orthogonal Type VI-A CRISPR-Cas enzymes”, Howard Hughes Medical Institute, Mol Cell, pp. 373-383, May 4, 2017. [cited by applicant]
Schmidt, et al., “Application of locked nucleic acids to improve aptamer in vivo stability and targeting function”, Nucleic Acids Research, vol. 32, No. 19, doi:10.1093/nar/gkh862, pp. 5757-5765, Oct. 27, 2004. [cited by applicant]
Makarova, et al., “Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants”, Nature Reviews | Microbiology, vol. 18, pp. 67-83, Feb. 2020. [cited by applicant]
Gleditzsch, et al., “PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures”, RNA Biology, vol. 16, No. 4, doi.org/10.1080/15476286.2018.1504546, pp. 504-517, Jul. 20, 2018. [cited by applicant]
Kellner, et al., “Sherlock: Nucleic acid detection with CRISPR nucleases”, Nat Protoc., doi:10.1038/s41596-019-0210-2, pp. 2986-3012, Oct. 2019. [cited by applicant]
Liu, et al., “Directed Evolution of CRISPR/Cas Systems for Precise Gene Editing”, Trends in Biotechnology, vol. 39, No. 3, Mar. 2021, p. 262-273. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/036610, dated Jun. 29, 2023, p. 1-93. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US22/52320, dated Jun. 15, 2023, p. 1-46. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/052032, dated Apr. 18, 2023, p. 1-19. [cited by applicant]
Zhang, et al, “An aM-level cascade CRISPR-Dx system (ASCas) for rapid detection of RNA without pre-amplification”, Biosensors and Bioelectronics, doi:10.1016/j.bios.2023.115248, Mar. 28, 2023, p. 1-5. [cited by applicant]
Zeng, et al., “Rapid RNA detection through intra-enzyme chain replacement-promoted Cas13a cascade cyclic reaction without amplification”, Analytica Chimica Acta, doi:10.1016/j.aca.2022.340009, May 31, 2022, p. 1-10. [cited by applicant]
Collias, et al., “CRISPR technologies and the search for the PAM-free nuclease”, Nature Communications, doi: 10.1038/s41467-020-20633-y, 2021, p. 1-12. [cited by applicant]
Huyke, et al., “Enzyme Kinetics and Detector Sensitivity Determine Limits of Detection of Amplification-Free CRISPR-Cas12 and CRISPR-Cas13 Diagnostics”, Analytical Chemistry, doi:10.1021/acs.analchem.2601670, Jun. 27, 2… [cited by applicant]
Mullally, et al., “5′ modifications to CRISPR-Cas9 gRNA can change the dynamics and size of R-loops and inhibit DNA cleavage”, Nucleic Acids Research, DOI:10.1093/nar/gkaa477, Jun. 2020, vol. 48, No. 12, p. 6811-6823. [cited by applicant]
Hong, et al., “Comparison and optimization of CRISPR/dCas9/gRNA genome-labeling systems for live cell imaging”, Genome Biology, DOI: 10.1186/s13059-018-1413-5, 2018, p. 7-8. [cited by applicant]
Li, et al., “CRISPR-Cas 12a has both cis- and trans-cleavage activities on single-stranded DNA”, Cell Research, DOI: 10.1038/s41422-018-0022-x, Feb. 5, 2018, p. 1-3. [cited by applicant]
Dong, et al., “An anti-CRISPR protein disables type V Cas12a by acetylation”, PubMed, DOI:10.1038/s41594-019-0206-1, Feb. 28, 2023, p. 1-1. [cited by applicant]
Coehlo, et al., “CRISPR Guard protects off-target sites from Cas9 nuclease activity using short guide RNAs”, Nature Communications, DOI: 10.1038/s41467-020-17952-5, Aug. 17, 2020, p. 1-12. [cited by applicant]
Click Chemistry, “Introduction: Click Chemistry”, Chem. Rev. 2021, doi/10.1021/acs.chemrev.1c00469, p. 6697-6698. [cited by applicant]
MacConnell, et al., “An Integrated Microfluidic Processor for DNA-Encoded Combinatorial Library Functional Screening”, ACS Combinatorial Science, DOI: 10.1021/acscombsci.6b00192, p. 181-192. [cited by applicant]
Mendes, et al., “High-throughput Identification of DNA-Encoded IgG Ligands that Distinquish Active and Latent [cited by applicant]
Gerry, et al., “Unifying principles of bifunctional, proximity-inducing small molecules”, Nat Chem Biol., Apr. 1, 2020, doi:10.1038/s41589-020-0469-1, p. 1-24. [cited by applicant]
Bowley, et al., “Libraries against libraries for combinatorial selection of replicating antigen-antibody pairs”, PNAS, Feb. 3, 2009, vol. 106, doi:10.1073/pnas.0812291106, p. 1380-1385. [cited by applicant]
Kempton, et al., “Multiple Input Sensing and Signal Integration Using a Split Cas12a System”, Molecular Cell, Apr. 2, 2020, p. 184-191. [cited by applicant]
Holt, et al., “By-passing selection: direct screening for antibody-antigen interactions using protein arrays”, Nucleic Acids Research, Jun. 16, 2000, vol. 28, No. 15, p. 1-5. [cited by applicant]
Delley, et al., “Microfluidic particle zipper enables controlled loading of droplets with distinct particle types”, Lab Chip., Jul. 14, 2020, doi:10.1039/d01c00339e, p. 2465-2472. [cited by applicant]
Betancur, et al., “miRNA-like duplexes as RNAi triggers with improved specificity”, Frontiers in Genetics, vol. 3, doi: 10.3389/fgene.2012.00127, pp. 1-6, Jul. 12, 2012. [cited by applicant]
Deng, et al., “Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing”, Nature Communications, doi.org/10.1038/s41467-024-46001-8, pp. 1-16, Mar.… [cited by applicant]
Koonin, et al., “Diversity, classification and evolution of CRISPR-Cas systems”, Current Opinion in Microbiology, 2017, 37, pp. 67-78, Jun. 9, 2017. [cited by applicant]
Zhou, et al., “High-throughput split-protein profiling by comgining transposon mutagenesis and regulated protein-protein interactions with deep sequencing”, International Journal of Biological Macromolecules, pp. 543-55… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US23/34598, dated Feb. 8, 2024, p. 1-25. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US23/34231, dated Feb. 16, 2024, p. 1-19. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US23/33554, dated Feb. 13, 2024, p. 1-23. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2024/022090, dated Jun. 12, 2024, p. 1-16. [cited by applicant]